Literature DB >> 26271463

Non-steroidal anti-inflammatory drugs and risk of cerebrovascular events in patients with osteoarthritis: a nested case-control study.

Francesco Lapi1, Carlo Piccinni2, Monica Simonetti3, Miriam Levi3,4, Pierangelo Lora Aprile5, Iacopo Cricelli3, Claudio Cricelli5, Andrea Fanelli6.   

Abstract

Recent studies show that the risk of cardiovascular adverse events for certain traditional non-steroidal anti-inflammatory drugs (NSAIDs) is similar to that of rofecoxib. While these results are focused on ischemic cardiomyopathy, there is little evidence concerning the risk of ischemic stroke/transient ischemic attack and hemorrhagic stroke. Additionally, there is no information on nimesulide and ketoprofen, the most frequently prescribed NSAIDs in Italy, along with diclofenac. This study aims to determine whether the use of NSAIDs is associated with an increased risk of cerebrovascular events in Italy. We performed a case-control analysis nested in a cohort of patients with osteoarthritis between 2002 and 2011 who were newly treated with NSAIDs. The patients were followed until December 31, 2012. Conditional logistic regression was used to estimate odds ratios (ORs) with 95% confidence intervals (95% CI) of cerebrovascular events (index date) associated with current (until 30 days before the index date), recent (31-365 days) and past (>365 days) use of NSAIDs. Within a cohort of 29,722 patients, 1566 cases (1546 matched with controls) were identified (incidence rate = 11.0/1000 person-years). The overall rate of cerebrovascular event was not elevated with current NSAIDs overall when compared with past use. Among individual NSAIDs, diclofenac and ketoprofen were the molecules significantly associated with an increased rate of cerebrovascular events (OR = 1.53; 95% CI 1.04-2.24; OR = 1.62; 95% CI 1.02-2.58, respectively). The most frequent event was hemorrhagic stroke following the use of ketoprofen (OR = 2.09; 95% CI 1.05-4.15). Diclofenac and ketoprofen seemed to increase the risk of cerebrovascular events. These findings might influence the choice of NSAIDs according to patient characteristics.

Entities:  

Keywords:  Cerebrovascular events; Drug safety; Non-steroidal anti-inflammatory drugs; Osteoarthritis

Mesh:

Substances:

Year:  2015        PMID: 26271463     DOI: 10.1007/s11739-015-1288-3

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN: 1828-0447            Impact factor:   3.397


  45 in total

1.  Cause-specific cardiovascular risk associated with nonsteroidal antiinflammatory drugs among healthy individuals.

Authors:  Emil Loldrup Fosbøl; Fredrik Folke; Søren Jacobsen; Jeppe N Rasmussen; Rikke Sørensen; Tina Ken Schramm; Søren S Andersen; Søren Rasmussen; Henrik Enghusen Poulsen; Lars Køber; Christian Torp-Pedersen; Gunnar H Gislason
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2010-06-08

2.  Selection of controls in case-control studies. III. Design options.

Authors:  S Wacholder; D T Silverman; J K McLaughlin; J S Mandel
Journal:  Am J Epidemiol       Date:  1992-05-01       Impact factor: 4.897

3.  Cyclooxygenase-2 selective nonsteroidal anti-inflammatory drugs and the risk of ischemic stroke: a nested case-control study.

Authors:  Frank Andersohn; René Schade; Samy Suissa; Edeltraut Garbe
Journal:  Stroke       Date:  2006-05-25       Impact factor: 7.914

4.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

5.  Adverse drug reactions associated with the use of NSAIDs: a case/noncase analysis of spontaneous reports from the French pharmacovigilance database 2002-2006.

Authors:  Maryse Lapeyre-Mestre; Sabrina Grolleau; Jean-Louis Montastruc
Journal:  Fundam Clin Pharmacol       Date:  2011-09-20       Impact factor: 2.748

6.  Risk of ischemic stroke associated with non-steroidal anti-inflammatory drugs and paracetamol: a population-based case-control study.

Authors:  P García-Poza; F J de Abajo; M J Gil; A Chacón; V Bryant; L A García-Rodríguez
Journal:  J Thromb Haemost       Date:  2015-02-24       Impact factor: 5.824

7.  Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis.

Authors:  A G Johnson; T V Nguyen; R O Day
Journal:  Ann Intern Med       Date:  1994-08-15       Impact factor: 25.391

Review 8.  Do selective cyclo-oxygenase inhibitors eliminate the adverse events associated with nonsteroidal anti-inflammatory drug therapy?

Authors:  Jacques Devière
Journal:  Eur J Gastroenterol Hepatol       Date:  2002-09       Impact factor: 2.566

9.  Cardiovascular events associated with rofecoxib: final analysis of the APPROVe trial.

Authors:  John A Baron; Robert S Sandler; Robert S Bresalier; Angel Lanas; Dion G Morton; Robert Riddell; Erik R Iverson; David L Demets
Journal:  Lancet       Date:  2008-10-14       Impact factor: 79.321

10.  Adherence to antihypertensive medications and cardiovascular morbidity among newly diagnosed hypertensive patients.

Authors:  Giampiero Mazzaglia; Ettore Ambrosioni; Marianna Alacqua; Alessandro Filippi; Emiliano Sessa; Vincenzo Immordino; Claudio Borghi; Ovidio Brignoli; Achille P Caputi; Claudio Cricelli; Lorenzo G Mantovani
Journal:  Circulation       Date:  2009-10-05       Impact factor: 29.690

View more
  5 in total

1.  NSAIDs and cardiovascular disease: time to say no to diclofenac.

Authors:  Patompong Ungprasert
Journal:  Intern Emerg Med       Date:  2015-08-26       Impact factor: 3.397

Review 2.  Cardiovascular and cerebrovascular risk with nonsteroidal anti-inflammatory drugs and cyclooxygenase 2 inhibitors: latest evidence and clinical implications.

Authors:  Andrea Fanelli; Daniela Ghisi; Pierangelo Lora Aprile; Francesco Lapi
Journal:  Ther Adv Drug Saf       Date:  2017-02-10

Review 3.  The Role of miRNAs in Common Inflammatory Arthropathies: Osteoarthritis and Gouty Arthritis.

Authors:  Panagiota Papanagnou; Theodora Stivarou; Maria Tsironi
Journal:  Biomolecules       Date:  2016-11-11

4.  NSAIDs utilization for musculoskeletal indications in elderly patients with cerebro/cardiovascular disease.

Authors:  Giuseppe Roberto; Claudia Bartolini; Federico Rea; Graziano Onder; Cristiana Vitale; Gianluca Trifirò; Ursula Kirchmayer; Alessandro Chinellato; Ersilia Lucenteforte; Giovanni Corrao; Alessandro Mugelli; Francesco Lapi; Rosa Gini
Journal:  Eur J Clin Pharmacol       Date:  2018-01-30       Impact factor: 2.953

5.  Women With Osteoarthritis Are at Increased Risk of Ischemic Stroke: A Population-Based Cohort Study.

Authors:  Chung-Hsin Yeh; Wei-Lun Chang; Po-Chi Chan; Chih-Hsin Mou; Ko-Shih Chang; Chung Y Hsu; Shiow-Luan Tsay; Min-Tein Tsai; Min-Hsien Hsu; Fung-Chang Sung
Journal:  J Epidemiol       Date:  2021-02-02       Impact factor: 3.211

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.